NORVASC FDA MedWatch Voluntary U.S. Reports Summary

These tables and charts are created from 2,071 U.S. reports for NORVASC (AMLODIPINE BESYLATE) voluntarily reported by individuals directly to the FDA via the MedWatch Reporting System from 2004 through July 30, 2026. Events listed on this page represent serious and often rare adverse events reported to the FDA, and often do not represent typical side effects for the medication. Find common side effects on the most recent official drug label.

For a summary of adverse events including mandatory reports submitted by pharmaceutical companies (all countries and all reporter types) to the FAERS database, View FDA FAERS NORVASC Report.

Top Adverse Events Reported with NORVASC (from U.S. FDA Medwatch Reports)

	Side Effect	# of FDA Reports
1	NAUSEA	116
2	DIARRHEA	114
3	DEATH	108
4	FATIGUE	106
5	SHORTNESS OF BREATH	92
6	DIZZINESS	91
7	LACK OF STRENGTH AND ENERGY (ASTHENIA)	87
8	HEADACHE	87
9	DRUG INEFFECTIVE	72
10	VOMITING	70
11	DISEASE PROGRESSION	66
12	JOINT PAIN	63
13	PRODUCT SUBSTITUTION ISSUE	61
14	PAIN	59
15	RASH	59
16	THERAPY CESSATION	59
17	DEHYDRATION	54
18	HOSPITALIZATION	50
19	THERAPY INTERRUPTED	47
20	URINARY TRACT INFECTION	45
21	ABDOMINAL PAIN	44
22	CONFUSIONAL STATE	44
23	FALL	44
24	ITCHING	44
25	PAIN IN EXTREMITY	43

Search all MedWatch Reports by Keyword:

NORVASC Total Medwatch Safety Reports by Patient Sex

Male	Female	Unknown	Total
837	1186	48	2,071

Medwatch Reporter Type	Count
Consumer	668
Physician	109
Pharmacist	442
Other Health Professional	372

Top Indications

HIGH BLOOD PRESSURE
Product used for unknown indication
Cardiac disorder
Blood pressure systolic
Blood pressure measurement

Type of Outcome Reported
Serious: 1551
Not Serious: 520
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.

Suspected Role
Primary Suspect: 2071
Concomitant Drugs: 2008
Note: A single MedWatch report can list more than one drug. This summary includes NORVASC identified as the suspect drug or as a concomitantly taken drug.

FDA Safety-Related Labeling Changes

NORVASC (AMLODIPINE BESYLATE) Rx Drug:
FDA Safety-related Labeling Changes

Have experience (good or bad) with NORVASC? Rate NORVASC at Ask a Patient.

For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.

NOTES

This report, created by AskaPatient.com, is derived from U.S. drug-related adverse event cases that were reported directly to the FDA using the voluntary MedWatch online or paper reporting system. MedWatch is the voluntary FDA system for consumers, physicians, and others to directly report adverse reactions. The Medwatch initiative was launched in 1993 as a voluntary reporting program for consumers, physicians and other healthcare practitioners.

After processing the received forms, the FDA adds the MedWatch reports to the FDA Adverse Events Reporting System(or FAERS database.) Click here for the complete FAERS report summary, which includes mandatory reports submitted by pharmaceutical companies (worldwide) combined with the MedWatch reports. MedWatch Reports only represent about 5% of the FAERS database. For more, read "Does the FDA's Rapidly Growing Database of Adverse Events Improve Drug Safety?"

The data in this report was obtained from Open FDA. Data was last updated to include reports through January 27, 2026. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event.

Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on Open FDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."

FDA uses the "MedDRA" classification system to describe reported adverse reactions. MedDRA is a standardized medical terminology that facilitates sharing of regulatory information internationally. In some cases, "patient friendly" terms for the layman designated by MedDRA have been substituted for medical jargon. Please contact us with questions about this report.